收费全文 | 11928篇 |
免费 | 806篇 |
国内免费 | 60篇 |
耳鼻咽喉 | 103篇 |
儿科学 | 186篇 |
妇产科学 | 141篇 |
基础医学 | 1582篇 |
口腔科学 | 200篇 |
临床医学 | 1172篇 |
内科学 | 2801篇 |
皮肤病学 | 397篇 |
神经病学 | 1206篇 |
特种医学 | 670篇 |
外科学 | 1783篇 |
综合类 | 38篇 |
一般理论 | 2篇 |
预防医学 | 500篇 |
眼科学 | 149篇 |
药学 | 691篇 |
中国医学 | 19篇 |
肿瘤学 | 1154篇 |
2023年 | 53篇 |
2022年 | 38篇 |
2021年 | 192篇 |
2020年 | 169篇 |
2019年 | 239篇 |
2018年 | 277篇 |
2017年 | 231篇 |
2016年 | 297篇 |
2015年 | 354篇 |
2014年 | 458篇 |
2013年 | 594篇 |
2012年 | 981篇 |
2011年 | 961篇 |
2010年 | 649篇 |
2009年 | 553篇 |
2008年 | 885篇 |
2007年 | 941篇 |
2006年 | 907篇 |
2005年 | 864篇 |
2004年 | 742篇 |
2003年 | 645篇 |
2002年 | 664篇 |
2001年 | 119篇 |
2000年 | 81篇 |
1999年 | 104篇 |
1998年 | 83篇 |
1997年 | 92篇 |
1996年 | 51篇 |
1995年 | 66篇 |
1994年 | 40篇 |
1993年 | 61篇 |
1992年 | 33篇 |
1991年 | 39篇 |
1990年 | 22篇 |
1989年 | 33篇 |
1988年 | 24篇 |
1987年 | 24篇 |
1986年 | 28篇 |
1985年 | 23篇 |
1984年 | 16篇 |
1983年 | 16篇 |
1982年 | 18篇 |
1981年 | 16篇 |
1979年 | 10篇 |
1978年 | 7篇 |
1977年 | 8篇 |
1976年 | 8篇 |
1975年 | 8篇 |
1974年 | 13篇 |
1973年 | 8篇 |
Background
There is evidence linking metformin to improved prostate cancer–related outcomes.Patients and Methods
Twenty-five men with metastatic castration-resistant prostate cancer and prostate-specific antigen (PSA) progression while receiving treatment with abiraterone from 3 Swiss centers were included in this single-arm phase 2 trial between November 2013 and September 2016. Metformin was added to abiraterone continuously at 1000 mg twice daily in uninterrupted 4-week cycles. The primary end point was the absence of disease progression at 12 weeks (PFS12). The Fleming single-stage design was applied. With a 5% significance level and 80% power, 25 patients were required to test PFS12 ≤ 15% (H0) compared to ≥ 35% (H1). Secondary end points included toxicity and safety issues. The study was registered at ClinicalTrials.gov (NCT01677897).Results
The primary end point PFS12 was 12% (3 of 25 patients) (95% confidence interval, 3-31). Most patients had PSA progression, almost half had radiographic progression, but only 1 patient had symptomatic progression. Eleven (44%) of 25 patients had grade 1 and 2 patients each grade 2 (8%) or grade 3 (8%) gastrointestinal toxicity (nausea, diarrhea, loss of appetite). One patient discontinued treatment at week 5 because of intolerable grade 3 diarrhea.Conclusion
The addition of metformin to abiraterone for patients with metastatic castration-resistant prostate cancer and PSA progression while receiving abiraterone therapy does not affect further progression and has no meaningful clinical benefit. A higher-than-expected gastrointestinal toxicity attributed to metformin was observed. 相似文献This study aimed at evaluating the marginal and internal adaptation of low-viscosity bulk-fill composites to enamel and dentin using a self-etch or an etch-and-rinse adhesive without and with artificial ageing. Hundred and twenty-eight MOD cavities in extracted molars were assigned to eight groups (n = 16), restored with the adhesives OptiBond FL (OFL) or Xeno V+ (X) and two low-viscosity bulk-fill composites SDR or x-tra base, covered with Premise. Tetric EvoCeram Bulk Fill and Premise served as a control. n = 8 per group were subjected to prolonged water storage (180 days) and thermocycling (2500×). Scanning electron microscopy was used to determine marginal gaps (MG) and interfacial adhesive defects (IAD). There were no significant differences between composite types in 44 out of 48 (MG) or 43/48 (IAD) comparisons. More MG were observed with X than with OFL (14 out of 16 comparisons, two significant), while in 16 of 16 comparisons with X more IAD were observed (14 significant). After artificial ageing, MG generally increased (9/16 significant), compared to IAD (one significant). The performance of the investigated composite types concerning the integrity of the tooth-composites interface was comparable. Compared to the 1-step self-etch system, the bond with the 3-step etch-and-rinse adhesive was raised.
相似文献